Frontiers in Genetics (Aug 2022)

Effects of the PLK4 inhibitor Centrinone on the biological behaviors of acute myeloid leukemia cell lines

  • Xing-Ru Mu,
  • Meng-Meng Ma,
  • Zi-Yi Lu,
  • Jun Liu,
  • Yu-Tong Xue,
  • Jiang Cao,
  • Ling-Yu Zeng,
  • Feng Li,
  • Kai-Lin Xu,
  • Kai-Lin Xu,
  • Qing-Yun Wu,
  • Qing-Yun Wu

DOI
https://doi.org/10.3389/fgene.2022.898474
Journal volume & issue
Vol. 13

Abstract

Read online

Polo-like kinase 4 (PLK4), a key regulator of centriole biogenesis, is frequently overexpressed in cancer cells. However, roles and the mechanism of PLK4 in the leukemiagenesis of acute myeloid leukemia (AML) remain unclear. In this study, the PLK4 inhibitor Centrinone and the shRNA knockdown were used to investigate roles and the mechanism of PLK4 in the leukemiagenesis of AML. Our results indicated that Centrinone inhibited the proliferation of AML cells in a dose- and time-dependent manner via reduced the expression of PLK4 both in the protein and mRNA levels. Moreover, colony formation assay revealed that Centrinone reduced the number and the size of the AML colonies. Centrinone induced AML cell apoptosis by increasing the activation of Caspase-3/poly ADP-ribose polymerase (PARP). Notably, Centrinone caused the G2/M phase cell cycle arrest by decreasing the expression of cell cycle-related proteins such as Cyclin A2, Cyclin B1, and Cyclin-dependent kinase 1 (CDK1). Consistent with above results, knockdown the expression of PLK4 also inhibited cell proliferation and colony formation, induced cell apoptosis, and caused G2/M phase cell cycle arrest without affecting cell differentiation. All in all, this study suggested that PLK4 inhibited the progression of AML in vitro, and these results herein may provide clues in roles of PLK4 in the leukemiagenesis of AML.

Keywords